WELLINGTON MANAGEMENT GROUP LLP 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-10 10:49 am Sale | 2024-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 11,833,409 9.500% | -3,766,120 (-24.14%) | Filing |
| 2024-11-08 10:52 am Sale | 2024-09-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 15,599,529 12.810% | -878,321 (-5.33%) | Filing |
| 2024-02-08 10:05 am Purchase | 2023-12-29 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 16,477,850 13.910% | 1,706,991 (+11.56%) | Filing |
| 2023-09-08 10:29 am Purchase | 2023-08-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 14,770,859 12.550% | 5,950,461 (+67.46%) | Filing |
| 2023-02-06 2:49 pm Sale | 2022-12-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 8,820,398 7.980% | -3,657,855 (-29.31%) | Filing |
| 2022-02-04 09:15 am Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 12,478,253 12.830% | 1,900,333 (+17.97%) | Filing |
| 2021-02-03 1:33 pm Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | WELLINGTON MANAGEMENT GROUP LLP | 10,577,920 13.970% | 295,290 (+2.87%) | Filing |